Evaluation of protein expression pattern of stanniocalcin 2, insulin-like growth factor-binding protein 7, inhibin beta A and four and a half LIM domains 1 in esophageal squamous cell carcinoma

Cancer Biomarkers

Volumn 12, Issue 1, 2012, Pages 1-9

  Kashyap, Manoj Kumar ^a,b,f,h   Pawar, Harsh A ^a,c,d   Keerthikumar, Shivakumar ^a,i   Sharma, Jyoti ^a,f   Goel, Renu ^a   Mahmood, Riaz ^b   Kumar, M Vijaya ^d   Kumar, K V Veerendra ^d   Pandey, Akhilesh ^f   Kumar, Rekha V ^c,d   Prasad, T S Keshava ^a,e,g   Harsha, H C ^a  

^a INSTITUTE OF BIOINFORMATICS   (India)

^b KUVEMPU UNIVERSITY   (India)

^c RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES   (India)

^d KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^e MANIPAL UNIVERSITY   (India)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g PONDICHERRY UNIVERSITY   (India)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Esophageal adenocarcinoma; Extracellular matrix; Invasion; Tumor suppression

Indexed keywords

BIOLOGICAL MARKER; INHIBIN BETA A; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 7; STANNIOCALCIN 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; DNA MICROARRAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TISSUE MICROARRAY;

CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; INHIBIN-BETA SUBUNITS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIM DOMAIN PROTEINS; MUSCLE PROTEINS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872833481     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-120289     Document Type: Article

References (40)

1. Levine MS. HR: Carcinoma of the esophagus, Philadelphia, PA: Saunders; 2000.
2. KashyapMK, MarimuthuA,KishoreCJ, Peri S,Keerthikumar S, Prasad TS,Mahmood R, Rao S, Ranganathan P, Sanjeeviah RC, et al. Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. Cancer Biol Ther, 8 (2009): 36-46.
3. Pawar H, KashyapMK, Sahasrabuddhe NA, Renuse S, Harsha HC, Kumar P, Sharma J, Kandasamy K, Marimuthu A, Nair B, Rajagopalan S, Maharudraiah J, Premalatha CS, Kumar KVV, Vijayakumar M, Chaerkady R, Prasad TSK, Kumar RV, Pandey A. Quantitative Tissue Proteomics of Esophageal Squamous Cell Carcinoma for Novel Biomarker Discovery. Cancer Biology & Therapy, 12 (2011): 510-522.
4. KashyapMK, Harsha HC, Renuse S, Pawar H, Sahasrabuddhe NA, Kim MS, Marimuthu A, Keerthikumar S, Muthusamy B, Kandasamy K, et al. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol Ther, 10 (2010): 796-810.
5. KashyapMK,Marimuthu A, Peri S, Kumar GSS, Jacob HCK, Prasad TSK, Mahmood R, Kumar KVV, Vijaya Kumar M, Meltzer SJ, et al. Overexpression of Periostin and Lumican in Esophageal Squamous Cell Carcinoma. Cancers, 2 (2010): 133-142.
6. Hubbi ME, Gilkes DM, Baek JH, Semenza GL. Four-and-ahalf LIM domain proteins inhibit transactivation by hypoxiainducible factor 1. J Biol Chem, 287 (2012): 6139-6149.
7. Jellinek DA, Chang AC, Larsen MR, Wang X, Robinson PJ, Reddel RR. Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. Biochem J, 350 (2000): 453-461.
8. Meyer HA, Tolle A, Jung M, Fritzsche FR, Haendler B, Kristiansen I, Gaspert A, Johannsen M, Jung K, Kristiansen G. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol, 55 (2009): 669-678.
9. Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, Reis-Filho JS, Isacke CM. Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin Cancer Res, 13 (2007): 3164-3173. (Pubitemid 46944898)
10. Yokobori T, Mimori K, Ishii H, Iwatsuki M, Tanaka F, Kamohara Y, Ieta K, Kita Y, Doki Y, Kuwano H, Mori M. Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann Surg Oncol, 17 (2010): 2601-2607.
11. Tamura K, Furihata M, Chung SY, Uemura M, Yoshioka H, Iiyama T, Ashida S, Nasu Y, Fujioka T, Shuin T, et al. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci, 100 (2009): 914-919.
12. Volland S,KuglerW, Schweigerer L,Wilting J, Becker J. Stanniocalcin 2 promotes invasion and is associatedwithmetastatic stages in neuroblastoma. Int J Cancer, 125 (2009): 2049-2057.
13. Kita Y, Mimori K, Iwatsuki M, Yokobori T, Ieta K, Tanaka F, Ishii H, Okumura H, Natsugoe S, Mori M: STC2. a predictive marker for lymph node metastasis in esophageal squamouscell carcinoma. Ann Surg Oncol, 18 (2011): 261-272.
14. Law AY, Wong CK. Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res, 316 (2010): 466-476.
15. Prasad TS, Kandasamy K, Pandey A. Human protein reference database and human proteinpedia as discovery tools for systems biology. Methods Mol Biol, 577 (2009): 67-79.
16. Heesch S, Schlee C, Neumann M, Stroux A, Kuhnl A, Schwartz S, Haferlach T, Goekbuget N, Hoelzer D, Thiel E, et al. BAALC-associated gene expression profiles define IGFBP7 as a novelmolecularmarker in acute leukemia. Leukemia, 24 (2010): 1429-1436.
17. Vizioli MG, SensiM,Miranda C, Cleris L, Formelli F, Anania MC, Pierotti MA, Greco A: IGFBP7. an oncosuppressor gene in thyroid carcinogenesis. Oncogene, 29 (2010): 3835-3844.
18. Ruan W,Wang Y, Ma Y, Xing X, Lin J, Cui J, Lai M. HSP60, a protein downregulated by IGFBP7 in colorectal carcinoma. J Exp Clin Cancer Res, 29 (2010): 41.
19. Hao Y, Triadafilopoulos G, Sahbaie P, Young HS, Omary MB, Lowe AW. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology, 131 (2006): 925-933. (Pubitemid 44307058)
20. Takeno A, Takemasa I, Doki Y, Yamasaki M, Miyata H, Takiguchi S, Fujiwara Y, Matsubara K, Monden M. Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis. Br J Cancer, 99 (2008): 1307-1315.
21. Bedogni B, Powell MB. Hypoxia, melanocytes and melanoma - survival and tumor development in the permissive microenvironment of the skin. Pigment Cell Melanoma Res, 22 (2009): 166-174.
22. Koga T, Endo H, Miyamoto Y, Mukai M, Akira S, Inoue M. IGFBPs contribute to survival of pancreatic cancer cells under severely hypoxic conditions. Cancer Lett, 268 (2008): 82-88.
23. Zhao L, He LR, Zhang R, Cai MY, Liao YJ, Qian D, Xi M, Zeng YX, Xie D, Liu MZ. Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma. Med Oncol, 29 (2012): 2669-2676.
24. Wang Q,Wen YG, Li DP, Xia J, Zhou CZ, Yan DW, Tang HM, Peng ZH. Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol, 29 (2012): 77-83.
25. Zhang X, Yang JJ, Kim YS, Kim KY, Ahn WS, Yang S. An 8-gene signature, including methylated and down-regulated glutathione peroxidase 3, of gastric cancer. Int J Oncol, 36 (2010): 405-414.
26. Zhang DF, Li XG, Su LJ, Meng QL. Expression of activin A and follistatin in glioblastoma and their effects on U87 in vitro. J IntMed Res, 38 (2010): 1343-1353.
27. Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, Beer DG. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia, 11 (2009): 388-396.
28. Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ,Chen G,Chang AC, OrringerMB, Beer DG. INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma. J Thorac Oncol, 4 (2009): 455-462.
29. Shimizu S, Seki N, Sugimoto T, Horiguchi S, Tanzawa H, Hanazawa T, Okamoto Y. Identification of molecular targets in head and neck squamous cell carcinomas based on genomewide gene expression profiling. Oncol Rep, 18 (2007): 1489-1497.
30. Cao D, Hustinx SR, Sui G, Bala P, Sato N,Martin S,Maitra A, MurphyKM, Cameron JL,Yeo CJ, et al. Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags. Cancer Biol Ther, 3 (2004): 1081-1089. (Pubitemid 41350988)
31. Sakashita K, Mimori K, Tanaka F, Kamohara Y, Inoue H, Sawada T, Hirakawa K, Mori M. Clinical significance of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol, 15 (2008): 2293-2300.
32. Xu Y, Liu Z, Guo K. Expression of FHL1 in gastric cancer tissue and its correlation with the invasion and metastasis of gastric cancer. Mol Cell Biochem, 363 (2012): 93-99.
33. Niu C, Liang C, Guo J, Cheng L, Zhang H, Qin X, Zhang Q, Ding L, Yuan B, Xu X, et al. Downregulation and growth inhibitory role of FHL1 in lung cancer. Int J Cancer, 130 (2012): 2549-2556.
34. Fryknas M, Wickenberg-Bolin U, Goransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Hoog A, Larsson C, Grimelius L, et al. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol, 27 (2006): 211-220.
35. Li X, Jia Z, ShenY, IchikawaH, Jarvik J,NageleRG, Goldberg GS. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci, 99 (2008): 1326-1333. (Pubitemid 351761720)
36. Asada K, Ando T, Niwa T, Nanjo S, Watanabe N, Okochi-Takada E, Yoshida T, Miyamoto K, Enomoto S, Ichinose M, et al. FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect. Oncogene, (2012).
37. Matsumoto M, Kawakami K, Enokida H, Toki K, Matsuda R, Chiyomaru T, Nishiyama K, Kawahara K, Seki N, Nakagawa M. CpG hypermethylation of human four-and-a-half LIM domains 1 contributes to migration and invasion activity of human bladder cancer. Int J Mol Med, 26 (2010): 241-247.
38. Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol, 119 (1993): 441-449. (Pubitemid 23165049)
39. Genini M, Schwalbe P, Scholl FA, Remppis A, Mattei MG, Schafer BW. Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma. DNA Cell Biol, 16 (1997): 433-442. (Pubitemid 27210442)
40. Johannessen M, Moller S, Hansen T, Moens U, Van Ghelue M. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci, 63 (2006): 268-284. (Pubitemid 43202310)